Immunovia Publ (Sweden) Math Transform Inverse Tangent Over Price Movement

IMMNOV Stock  SEK 0.41  0.02  5.13%   
Immunovia Publ math transform tool provides the execution environment for running the Inverse Tangent Over Price Movement transformation and other technical functions against Immunovia Publ. Immunovia Publ value trend is the prevailing direction of the price over some defined period of time. The concept of trend is an important idea in technical analysis, including the analysis of math transform indicators. As with most other technical indicators, the Inverse Tangent Over Price Movement transformation function is designed to identify and follow existing trends. Analysts that use price transformation techniques rely on the belief that biggest profits from investing in Immunovia Publ can be made when Immunovia Publ shifts in price trends from positive to negative or vice versa.

Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. Immunovia publ AB Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Immunovia Publ price patterns.

Immunovia Publ Technical Analysis Modules

Most technical analysis of Immunovia Publ help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Immunovia from various momentum indicators to cycle indicators. When you analyze Immunovia charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Immunovia Publ Predictive Technical Analysis

Predictive technical analysis modules help investors to analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Immunovia publ AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Immunovia publ AB based on widely used predictive technical indicators. In general, we focus on analyzing Immunovia Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Immunovia Publ's daily price indicators and compare them against related drivers, such as math transform and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Immunovia Publ's intrinsic value. In addition to deriving basic predictive indicators for Immunovia Publ, we also check how macroeconomic factors affect Immunovia Publ price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Hype
Prediction
LowEstimatedHigh
0.020.413.80
Details
Intrinsic
Valuation
LowRealHigh
0.020.393.78
Details

Be your own money manager

As an individual investor, you need to find a reliable way to track all your investment portfolios' performance accurately. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing you full analytical transparency into your positions, our tools can tell you how much better you can do without increasing your risk or reducing expected return.

Generate Optimal Portfolios

Align your risk and return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Other Information on Investing in Immunovia Stock

Immunovia Publ financial ratios help investors to determine whether Immunovia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immunovia with respect to the benefits of owning Immunovia Publ security.